64B13-18.002: Formulary of Topical Ocular Pharmaceutical Agents
PURPOSE AND EFFECT: The purpose of the amendment is to incorporate a new medication requested by the Florida Optometric Association, to which the TOPA Committee did not raise an objection, and to implement the Board’s determination that Azasite in the existing rule language is the brand name of the medication, not the chemically generic name, and its instruction that the amendment correct the name Azasite to Azithromycin.
SUMMARY: A new medication requested by the Florida Optometric Association, to which the TOPA Committee did not raise an objection, is incorporated, and the Board’s determination that Azasite in the existing rule language is the brand name of the medication, not the chemically generic name, and its instruction that the amendment correct the name Azasite to Azithromycin is implemented.
SUMMARY OF STATEMENT OF ESTIMATED REGULATORY COSTS: The Board determined that the proposed rule will not have an impact on small business. No Statement of Estimated Regulatory Cost was prepared.
Any person who wishes to provide information regarding a statement of estimated regulatory costs, or provide a proposal for a lower cost regulatory alternative must do so in writing within 21 days of this notice.
SPECIFIC AUTHORITY: 463.005, 463.0055(2)(a) FS.
LAW IMPLEMENTED: 463.0055 FS.
IF REQUESTED WITHIN 21 DAYS OF THE DATE OF THIS NOTICE, A HEARING WILL BE SCHEDULED AND ANNOUNCED IN FAW.
THE PERSON TO BE CONTACTED REGARDING THE PROPOSED RULE IS: Joe Baker, Jr., Executive Director, Board of Optometry, 4052 Bald Cypress Way, Bin C07, Tallahassee, Florida 32399-3259
THE FULL TEXT OF THE PROPOSED RULE IS:
64B13-18.002 Formulary of Topical Ocular Pharmaceutical Agents.
The topical ocular pharmaceutical formulary consists of pharmaceutical agents which a certified optometrist is qualified to administer and prescribe in the practice of optometry pursuant to Section 463.0055(2)(a), F.S. The topical ocular pharmaceutical agents in the formulary include the following legend drugs alone or in combination in concentrations up to those specified, or any lesser concentration that is commercially available:
(1) through (3) No change.
(a) through (l) No change.
(m) Moxifloxacin – 0.5%;
(n) Sodium sulfacetamide – 10.0% (alone and in combination);
(o) Azithromycin – 1%; and
(p) Levofloxacin – 1.5%
(5) through (8) No change.
(a) Hydroxypropyl cellulose ophthalmic Insert;
(b) Dapiprazole – 0.5%;
(c) Cyclosporine emulsion – 0.05%; and
(d) Polyvinyl pyrrolidone – drops 2.0%.
Specific Authority 463.005, 463.0055(2)(a) FS. Law Implemented 463.0055 FS. History–New 3-30-87, Amended 4-5-88, 5-7-90, Formerly 21-18.002, Amended 5-10-92, 1-29-93, Formerly 21Q-18.002, Amended 8-31-93, 7-30-94, Formerly 61F8-18.002, Amended 2-11-96, 4-21-96, 1-12-97, 6-8-97, Formerly 59V-18.002, Amended 6-15-00, 6-7-05, 6-10-06, 6-26-08,________.